Sun Pharmaceutical Industries Limited (($IN:SUNPHARMA)) announced an update on their ongoing clinical study. Sun Pharmaceutical Industries Limited ...

Tirbanibulin ointment 1% shows good safety and tolerability in the treatment of actinic keratosis (AK) in fields of up to 100 cm 2 on the face and scalp. The most common local effects of treatment ...

Actinic keratosis (AK) is a common precancerous lesion arising from cumulative ultraviolet exposure, often heralding the development of non-melanoma skin cancers such as basal cell carcinoma and ...

Credit: Almirall. The expanded approval was based on data from a phase 3 safety study which evaluated tirbanibulin in more than 100 adult patients with actinic keratosis. Findings showed the safety ...

Woburn, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), and ...

Please provide your email address to receive an email when new articles are posted on . The supplemental new drug application approved for Ameluz topical gel 10% increases the maximal dose from one to ...

The US Food and Drug Administration has approved a supplemental new drug application for tirbanibulin topical ointment, allowing the expansion of the surface area treated for actinic keratosis (AK) of ...

The announcement followed the release of the RhodoLED XL red light-emitting lamp, to be used in combination with aminolevulinic acid hydrochloride topical gel, 10% for actinic keratoses. The ...

Avoid long-term exposure to sunlight, especially for white-skinned people. Occupational exposure to UV light should also be avoided. Actinic keratosis is a pre-malignant lesion and may give rise to ...

Far from doffing their caps to actinic keratosis (AK), dermatology drug developers Almirall and Biofrontera are keeping things firmly covered to raise awareness of the skin cancer precursor. Ahead of ...